pentoxifylline has been researched along with Chronic Kidney Diseases in 21 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pentoxifylline (PTX) is a promising therapeutic approach for reducing inflammation and improving anemia associated to various systemic disorders." | 8.91 | Pentoxifylline for Anemia in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. ( Bolignano, D; Coppolino, G; D'Arrigo, G; Pisano, A, 2015) |
| "The aim of this study was to assess the effect of pentoxifylline on proteinuria and renal function in chronic kidney disease (CKD) treatment." | 4.93 | Effect of pentoxifylline in proteinuric chronic kidney disease: a systematic review and meta-analysis. ( Cui, M; Jiang, X; Kong, X; Yao, J; Zhou, S, 2016) |
| "Pentoxifylline (PTX) is a promising therapeutic approach for reducing inflammation and improving anemia associated to various systemic disorders." | 4.91 | Pentoxifylline for Anemia in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. ( Bolignano, D; Coppolino, G; D'Arrigo, G; Pisano, A, 2015) |
| "Pentoxifylline treatment (400 mg/twice a day) or standard treatment." | 2.90 | Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial. ( Barbieri, D; Carbayo, J; de Jose, AP; de Morales, AM; Delgado, A; Goicoechea, M; Luño, J; Verdalles, U; Verde, E, 2019) |
| "Pentoxifylline has been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the Handling Erythropoietin Resistance with Oxpentifylline multicentre double-blind, randomized controlled trial." | 2.84 | Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. ( Badve, SV; Cass, A; Clarke, P; Ferrari, P; Gummer, J; Hawley, CM; Johnson, DW; McDonald, SP; Morrish, AT; Olynyk, JK; Pascoe, EM; Pedagogos, E; Perkovic, V; Reidlinger, D; Scaria, A; Trengove, R; Vergara, LA; Walker, R, 2017) |
| " CTP-499 was well tolerated with no serious or severe adverse events, or adverse events leading to discontinuation." | 2.82 | A First-in-Patient, Multicenter, Double-Blind, 2-Arm, Placebo-Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP-499, in Chronic Kidney Disease. ( Braman, V; Cheng, C; Dao, M; Graham, P; Liu, J; Neutel, J; Sabounjian, L; Shipley, J; Wu, L, 2016) |
| "Patients with chronic kidney diseases (CKD) are often treated with antiplatelets due to aberrant haemostasis." | 1.62 | The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment. ( Chen, JY; Chen, YC; Fang, JH; Ho, CH; Hsing, CH; Liang, FW; Wu, CC, 2021) |
| "In terms of the risks of developing ESRD, pentoxifylline alone exerted a comparable beneficial effect to combined therapy with an RAAS inhibitor and greater renoprotection than RAAS inhibitor monotherapy." | 1.42 | Pentoxifylline Decreases Dialysis Risk in Patients With Advanced Chronic Kidney Disease. ( Chen, CY; Chen, L; Chen, YM; Huang, TM; Lin, CJ; Lin, SL; Pan, CF; Wu, CH; Wu, CJ; Wu, PC; Wu, VC, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 20 (95.24) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, H | 1 |
| Juang, SY | 1 |
| Liao, KF | 1 |
| Chen, YH | 1 |
| Fang, JH | 1 |
| Chen, YC | 1 |
| Ho, CH | 1 |
| Chen, JY | 1 |
| Hsing, CH | 1 |
| Liang, FW | 1 |
| Wu, CC | 1 |
| Chen, YM | 3 |
| Chiang, WC | 3 |
| Lin, SL | 2 |
| Tsai, TJ | 2 |
| Navarro-González, JF | 1 |
| Sánchez-Niño, MD | 1 |
| Donate-Correa, J | 1 |
| Martín-Núñez, E | 1 |
| Ferri, C | 1 |
| Pérez-Delgado, N | 1 |
| Górriz, JL | 1 |
| Martínez-Castelao, A | 1 |
| Ortiz, A | 1 |
| Mora-Fernández, C | 1 |
| de Morales, AM | 1 |
| Goicoechea, M | 1 |
| Verde, E | 1 |
| Carbayo, J | 1 |
| Barbieri, D | 1 |
| Delgado, A | 1 |
| Verdalles, U | 1 |
| de Jose, AP | 1 |
| Luño, J | 1 |
| Murkamilov, IT | 1 |
| Aitbaev, KA | 1 |
| Fomin, VV | 1 |
| Murkamilova, ZA | 1 |
| Bayzhigitova, AA | 1 |
| Mettang, T | 1 |
| Kremer, AE | 1 |
| Chen, PM | 2 |
| Lai, TS | 2 |
| Chen, PY | 2 |
| Lai, CF | 1 |
| Wu, V | 1 |
| Wu, KD | 1 |
| Kao, CC | 1 |
| Wu, MS | 1 |
| Antunes, SA | 1 |
| Vilela, RQ | 1 |
| Vaz, JD | 1 |
| Canziani, ME | 1 |
| Johnson, DW | 2 |
| Pascoe, EM | 2 |
| Badve, SV | 2 |
| Dalziel, K | 1 |
| Cass, A | 2 |
| Clarke, P | 2 |
| Ferrari, P | 2 |
| McDonald, SP | 2 |
| Morrish, AT | 2 |
| Pedagogos, E | 2 |
| Perkovic, V | 2 |
| Reidlinger, D | 2 |
| Scaria, A | 2 |
| Walker, R | 2 |
| Vergara, LA | 2 |
| Hawley, CM | 2 |
| He, T | 1 |
| Cooper, ME | 1 |
| Wu, PC | 1 |
| Wu, CJ | 1 |
| Lin, CJ | 1 |
| Pan, CF | 1 |
| Chen, CY | 1 |
| Huang, TM | 1 |
| Wu, CH | 1 |
| Chen, L | 1 |
| Wu, VC | 1 |
| Bolignano, D | 2 |
| D'Arrigo, G | 1 |
| Pisano, A | 2 |
| Coppolino, G | 2 |
| Jiang, X | 1 |
| Zhou, S | 1 |
| Yao, J | 1 |
| Kong, X | 1 |
| Cui, M | 1 |
| Kuo, KL | 1 |
| Hung, SC | 1 |
| Liu, JS | 1 |
| Chang, YK | 1 |
| Hsu, CC | 1 |
| Tarng, DC | 1 |
| Leporini, C | 1 |
| Russo, E | 1 |
| D Arrigo, G | 1 |
| de Sarro, G | 1 |
| Gummer, J | 1 |
| Trengove, R | 1 |
| Olynyk, JK | 1 |
| Sabounjian, L | 1 |
| Graham, P | 1 |
| Wu, L | 1 |
| Braman, V | 1 |
| Cheng, C | 1 |
| Liu, J | 1 |
| Shipley, J | 1 |
| Neutel, J | 1 |
| Dao, M | 1 |
| Pena-Polanco, JE | 1 |
| Fried, LF | 1 |
7 reviews available for pentoxifylline and Chronic Kidney Diseases
| Article | Year |
|---|---|
Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update.
Topics: Disease Progression; Kidney Failure, Chronic; Pentoxifylline; Phosphodiesterase Inhibitors; Proteinu | 2017 |
Pentoxifylline and nephroprotection: effects on renal dysfunction and cardiovascular risks.
Topics: Cardiovascular Diseases; Disease Progression; Humans; Kidney; Pentoxifylline; Renal Insufficiency, C | 2019 |
Uremic pruritus.
Topics: Acupuncture Therapy; Amines; Anti-Inflammatory Agents; Calcium Channel Blockers; Cyclohexanecarboxyl | 2015 |
Pentoxifylline for Anemia in Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
Topics: Adult; Anemia; Anti-Inflammatory Agents; Female; Humans; Male; Pentoxifylline; Phosphodiesterase Inh | 2015 |
Effect of pentoxifylline in proteinuric chronic kidney disease: a systematic review and meta-analysis.
Topics: Chi-Square Distribution; Glomerular Filtration Rate; Humans; Kidney; Odds Ratio; Pentoxifylline; Pho | 2016 |
Effect of pentoxifylline on renal outcomes in chronic kidney disease patients: A systematic review and meta-analysis.
Topics: Humans; Kidney; Pentoxifylline; Proteinuria; Randomized Controlled Trials as Topic; Renal Insufficie | 2016 |
Established and Emerging Strategies in the Treatment of Chronic Kidney Disease.
Topics: Allopurinol; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bicarbonate | 2016 |
6 trials available for pentoxifylline and Chronic Kidney Diseases
| Article | Year |
|---|---|
Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease.
Topics: Adult; Aged; Albuminuria; Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Nephropathie | 2018 |
Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Albuminuria; Cardiovascular Diseases; Creatinine; Disease Progression; Foll | 2019 |
Pentoxifylline does not alter the concentration of hepcidin in chronic kidney disease patients undergoing hemodialysis.
Topics: Adult; Aged; Anemia; Anti-Inflammatory Agents; Combined Modality Therapy; Female; Ferritins; Hemoglo | 2014 |
A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
Topics: Adult; Aged; Anemia; Cost Savings; Double-Blind Method; Drug Monitoring; Drug Resistance; Drug Syner | 2015 |
Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
Topics: Aged; Aged, 80 and over; Anemia; Biomarkers; Darbepoetin alfa; Double-Blind Method; Drug Resistance; | 2017 |
A First-in-Patient, Multicenter, Double-Blind, 2-Arm, Placebo-Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP-499, in Chronic Kidney Disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind M | 2016 |
8 other studies available for pentoxifylline and Chronic Kidney Diseases
| Article | Year |
|---|---|
Comparing the Effect of Folic Acid and Pentoxifylline on Delaying Dialysis Initiation in Patients with Advanced Chronic Kidney Disease.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Disease Progression; Female; Folic Acid; | 2019 |
The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment.
Topics: Adolescent; Adult; Aged; Databases, Factual; Female; Gastrointestinal Hemorrhage; Humans; Intracrani | 2021 |
Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi | 2014 |
Reply to comment on "Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease".
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Female; Humans; Kidney; | 2015 |
Renoprotective effect of pentoxifylline in advanced chronic kidney disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropathies; | 2015 |
Diabetic nephropathy: renoprotective effects of pentoxifylline in the PREDIAN trial.
Topics: Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Free Radi | 2014 |
Pentoxifylline Decreases Dialysis Risk in Patients With Advanced Chronic Kidney Disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; | 2015 |
Add-on Protective Effect of Pentoxifylline in Advanced Chronic Kidney Disease Treated with Renin-Angiotensin-Aldosterone System Blockade - A Nationwide Database Analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Creatinine; Databases, Fac | 2015 |